MODERN TECHNOLOGIES IN SQUAMOUS-CELL ANAL CANCER RADIOTHERAPY PLANNING AND TREATMENT
https://doi.org/10.17650/2220-3478-2013-0-3-50-55
Abstract
Squamous-cell anal cancer is a rare disease that requires a comprehensive approach in treatment and skilled professionals. Modern diagnostics is important for rational choice of treatment tactics. Radiotherapy is the cornerstone of sphincter-sparing anal cancer treatment. Radiotherapy dose, volume and duration are the key factors affecting treatment efficacy and toxicity.3D-conformal radiotherapy is a priority treatment allowing exact reproduction of treatment conditions, controlled by OBI (on-board imager) and kV X-Ray and cone-beam CT analysis. Intensity-modulated radiation therapy (IMRT) is a next-generation treatment with improved technologies, allowing better protection of normal tissues.Our experience with 21 squamous-cell anal cancer patients treated with IMRT during Nov 2011 – March 2013 is presented in this article.
About the Authors
S. I. Tkachev
N.N. Russian Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. V. Glebovskaya
N.N. Russian Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
I. P. Yazhgunovich
N.N. Russian Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. V. Vodyanik
N.N. Russian Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Кныш В.И., Тимофеев Ю.М. Злокачественные опухоли анального канала. М., 1997. С. 12.
2. Ткачев С.И., Глебовская В.В., Тимофеев Ю.М. Применение комбинированного консервативного метода лечения больных плоскоклеточным раком анального канала. Мат. III Всероссийского национального конгресса лучевых диагностов и терапевтов «Радиология 2009». Москва, 26–29 мая 2009 г. С. 412.
3. Ткачев С.И., Барсуков Ю.А., Глебовская В.В. Патент РФ № 2427399 Способ лечения плоскоклеточного рака анального канала.
4. Аминев А.М. Руководство по проктологии. Т. 1. Куйбышев, 1965. С. 518.
5. Singh R., Nime F., Mittelman A. Malignant epithelian tumors of the anal canal. Cancer 1981;48(2):411–5.
6. Жданов Д.А. Общая анатомия и физиология лимфатической системы. Л.: Медгиз, 1952. С. 336.
7. NCCN Clinical practice guidelines in oncology: anal carcinoma. V. 1. 2013. URL: http://www.nccn.org (дата обращения 01.02.2013).
8. Brown G., Dighe S., Taylor F. Clinical staging: CT and MRI. Current Clinical Oncology: Rectal Cancer. Springer, 2010. P. 21–35.
9. Leichman L., Nigro N., Vaitkevicius V.K. et al. Cancer of the anal canal: model for preoperative adjuvant combined modality therapy. Am J Med 1985;78:211–5.
10. Bartelink H., Roelofsen F., Eschwege F. et al. Concomitant radiotherapy and chemo-therapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15(5):2040–9.
11. Nigro N.D., Seydel H.G., Considine B. Jr et al. Combined radiotherapy and chemo-therapy for squamous cell carcinoma of the anal canal. Cancer 1983;51:1826–9.
12. Glynne-Jones R. Anal cancer: an examination of radiotherapy strategies. Int J Radiat Oncol Biol Phys 2011;79(5):1290–301.
13. Ярмоненко С.П., Вайнсон А.А., Коноплянников А.Г. Клиническая радиобиология. М.: Медицина, 1992. 320 c.
14. Dubois J.B., Vieillot S., Moscardo C.L. et al. A Planning Study to Compare Plans Using Volumetric Arc Therapy or IMRT for the Treatment of Anal Canal Cancer. URL:http://www.abstractsonline.com (дата обращения 01.08.2013).
15. Bilimoria K.Y., Bentrem D.J., Rock C.E. et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009;52:624–31.
16. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049–54.
17. Ajani J.A., Winter K.A., Gunderson L.L. et al. Fluorouracil, mitomicin and radiotherapy vs fluorocil, cisplatin and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008;299(16):1914–21.
18. Peiffert D., Gerard J.P., Ducreux M. et al. Induction chemotherapy (ICTA) and dose intercification of the radiation boost inlocally advanced anal canal carcinoma (LAACC): Definitive analysis of the Inter-group Accord 03 trial Fondation Francaise de Cancerologie Digestive. Radiother Oncol 2008;88(Suppl 2):S20 (abstract 65).
19. Marks L.B., Yorke E.D., Jackson A. et al.Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10–S9.
20. Fleshner P.R., Chalasani S., Chang G.J. et al. Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2008;51:2–9.
21. Saarilahti K., Arponen P., Vaalavirta L., Tenhunen M. The effect of intensity- modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008;87:383–90.
22. Trautmann T.G., Zuger J.H. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005;7:309–13.
Review
Views:
688
Email this article 